| Date Checked | 2025-12-21 23:39:18 |
|---|---|
| Graham Number | (PB)nan vs (PE)0.00 |
| Over / Under Value Percentage | 0.00% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | 2019-08-30 |
| Symbol | DMTK |
| AssetType | Common Stock |
| Name | DermTech Inc |
| Description | DermTech, Inc., a molecular diagnostics company, develops and markets new non-invasive genomic tests to diagnose skin cancer, inflammatory diseases, and age-related conditions in the United States. The company is headquartered in La Jolla, California. |
| CIK | 1651944 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | SERVICES-MEDICAL LABORATORIES |
| Address | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA, CA, US |
| FiscalYearEnd | December |
| LatestQuarter | 2023-06-30 |
| MarketCapitalization | 76115000 |
| EBITDA | -114813000 |
| PERatio | 0 |
| PEGRatio | None |
| BookValue | 2.636 |
| DividendPerShare | 0 |
| EPS | -3.83 |
| RevenuePerShareTTM | 0.457 |
| ProfitMargin | 0 |
| OperatingMarginTTM | -8.32 |
| ReturnOnAssetsTTM | -0.391 |
| ReturnOnEquityTTM | -0.897 |
| RevenueTTM | 14024000 |
| GrossProfitTTM | 647000 |
| DilutedEPSTTM | -3.83 |
| QuarterlyEarningsGrowthYOY | 0 |
| QuarterlyRevenueGrowthYOY | -0.06 |
| AnalystTargetPrice | 5.1 |
| TrailingPE | - |
| ForwardPE | - |
| PriceToSalesRatioTTM | 4.361 |
| PriceToBookRatio | 0.435 |
| EVToRevenue | 0.11 |
| EVToEBITDA | 0.518 |
| Beta | 2.534 |
| 52WeekHigh | 6.44 |
| 52WeekLow | 1.44 |
| 50DayMovingAverage | 2.761 |
| 200DayMovingAverage | 3.205 |
| SharesOutstanding | 33679100 |
| ExDividendDate | None |
| dateChecked | 2025-12-21 23:39:18 |
| fresh | 1 |